Allergan’s net revenue for the fourth quarter 2016 rose 7 percent to $3.86 billion, mostly driven by better sales of Botox, Linzess and certain other new products.
The sales brought Net Revenues of $14.57 billion for the year, while the partial offset was due to lower revenues from Namenda XR and loss of exclusivity of Asacol HD, Allergan said in its financial report on Wednesday.
As the company says, the increase in sales was driven by growth across main therapeutic areas and products, and a full year impact of acquired Allergan brands, including the $2.9 billion purchase of Acelity’s subsidiary LifeCell, adding commercial products to its regenerative medicine portfolio.
Launching nine products in 2017
Allergan said it plans to launch nine products in 2017. Brent Saunders, Chairman and CEO of Allergan, said: “Our R&D team continued to advance key programs and deliver FDA approvals for new products that change lives. And we made fast progress in our capital deployment program, enhancing short- and long-term value for our shareholders.”